BeOne Medicines (NASDAQ:ONC) Issues Quarterly Earnings Results

BeOne Medicines (NASDAQ:ONC) issued its quarterly earnings data on Thursday. The company reported $3.64 EPS for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30, Zacks reports. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q3 revenue and profitability accelerated: Product revenue rose 33% year over year to about $1.9 billion, while GAAP operating income increased 157% to $419 million. BeOne raised its 2026 revenue outlook to $6.9 billion–$7.0 billion and increased its operating-income guidance.
• BRUKINSA continued to drive growth: Global sales grew 34% to $1.4 billion, with U.S. sales exceeding $1 billion for the first time. Management pointed to strong new-patient starts and real-world evidence, while noting that U.S. sales benefited by about $50 million from order timing.
• Pipeline progress broadened across hematology and solid tumors: BeOne reported encouraging early data for several solid-tumor programs and advanced its B7-H4 ADC into a Phase III trial. The company also said its BTK degrader met the primary endpoint in a Phase II CLL study and that its treatment-naive mantle-cell lymphoma application received FDA priority review.
• Some expected returns may take longer, and investment will remain high: After FDA discussions, BeOne shifted its planned accelerated-approval filing for the BTK degrader in relapsed/refractory CLL to mid-2027, citing a request for additional follow-up. Management expects 2027 operating-expense growth to remain substantial, moderating the pace of margin expansion; it also flagged potential revenue pressure for XGEVA and KYPROLIS from biosimilars and possible China VBP inclusion.

BeOne Medicines Stock Up 2.5%

Shares of NASDAQ ONC traded up $9.47 during midday trading on Thursday, reaching $387.25. 959,362 shares of the company’s stock were exchanged, compared to its average volume of 395,963. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $405.00. The business’s fifty day moving average price is $362.80 and its two-hundred day moving average price is $325.98. The stock has a market capitalization of $42.52 billion, a PE ratio of 66.51 and a beta of 0.63.

Wall Street Analysts Forecast Growth

ONC has been the topic of several analyst reports. Guggenheim raised their target price on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, October 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $470.00 price objective on shares of BeOne Medicines in a research report on Thursday. Nomura boosted their target price on shares of BeOne Medicines from $454.75 to $484.91 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Barclays upped their target price on shares of BeOne Medicines from $407.00 to $415.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $424.26.

Insiders Place Their Bets

In other BeOne Medicines news, CEO John Oyler sold 115,011 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the transaction, the chief executive officer directly owned 125,799 shares of the company’s stock, valued at $45,019,688.13. This represents a 47.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 376,373 shares of company stock worth $134,848,154. Company insiders own 6.19% of the company’s stock.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 earnings per share of $3.64, above the $2.34 consensus estimate. Reports also said revenue and adjusted earnings rose, and the company increased its 2026 revenue outlook—signals of stronger performance and improved expectations. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review for a BRUKINSA combination in first-line mantle cell lymphoma. A potential label expansion could broaden the drug’s use, though priority review is not an approval. FDA Priority Review for BRUKINSA Combination

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.